Five rabbits treated with the thromboxane synthetase inhibitor Dazoxiben and five control rabbits received pig renal xenografts. Plasma albumin, complement factor C3, TXB2, 6-keto-PGF1 alpha, and serum TXB2 and 6-keto-PGF1 alpha were determined before and 1/2 hour after transplantation. The xenograft survival was significantly decreased in the Dazoxiben treated animals compared to the placebo treated animals determined as time to total cyanosis of the graft, total urine production, and time to stop of urine production. Lack of TXB2 production during blood coagulation confirmed inhibition of platelet thromboxane synthesis. The other determined variables showed no significant differences between the treated and the placebo animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0049-3848(83)90060-9 | DOI Listing |
Mol Cell Probes
January 2025
Department of Urology Surgery, Lanzhou University Second Hospital, Lanzhou, 730030, China. Electronic address:
Background: ARPC1B has been identified as a key regulator of malignant biological behavior in various tumors. However, its specific role in clear cell renal cell carcinoma (ccRCC) remains poorly understood. This study aims to evaluate the influence of ARPC1B on the prognosis and disease progression in ccRCC patients.
View Article and Find Full Text PDFBMC Urol
January 2025
Institute of Clinical Medicine, The Second affiliated Hospital of Hainan Medical University, 368th Yehai Avenue, Haikou, Hainan, 570311, China.
Background: Clear cell renal cell carcinoma (ccRCC) is the most common malignant urological tumor, and regrettably, and is insensitive to chemotherapy and radiotherapy, resulting in poor patient outcomes. DBF4 plays a critical role in DNA replication and participates in various biological functions, making it an attractive target for cancer treatment. However, its significance in ccRCC has not yet been explored.
View Article and Find Full Text PDFCancer Treat Res Commun
January 2025
Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA. Electronic address:
Clear cell renal cell carcinoma (ccRCC) poses a significant global health challenge as its incidence continues to rise, resulting in a substantial annual mortality rate. Major clinical challenges to current ccRCC treatments include high drug-resistance rates as well as dose-limiting adverse events; underlining the need to identify additional 'druggable' targets. TGF-β1, VEGF, and PD-L1 are potential therapeutic targets in ccRCC.
View Article and Find Full Text PDFMol Oncol
January 2025
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Italy.
Obesity exacerbates the risk and aggressiveness of many types of cancer. Adipose tissue (AT) represents a prevalent component of the tumor microenvironment (TME) and contributes to cancer development and progression. Reciprocal communication between cancer and adipose cells leads to the generation of cancer-associated adipocytes (CAAs), which in turn foster tumor invasiveness by producing paracrine metabolites, adipocytokines, and growth factors.
View Article and Find Full Text PDFCell Signal
January 2025
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Kunming Medical University, Kunming, China. Electronic address:
Clear cell renal cell carcinoma (ccRCC), a predominant subtype of renal cell carcinoma, significantly contributes to the heightened morbidity and mortality in individuals diagnosed with urologic tumors. The challenges posed by high malignancy at the initial diagnosis of ccRCC, therapeutic resistance, and unfavorable patient prognosis remain largely unresolved. Our findings indicate that SEPT5 is upregulated in ccRCC and this upregulation is associated with an adverse prognosis for ccRCC patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!